# Infliximab Plus Methotrexate for the Treatment of Rheumatoid Arthritis

> **NCT00269867** · PHASE3 · COMPLETED · sponsor: **Centocor, Inc.** · enrollment: 428 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Placebo
- **DRUG:** Infliximab 3 mg/kg
- **DRUG:** Infliximab 10 mg/kg

## Key facts

- **NCT ID:** NCT00269867
- **Lead sponsor:** Centocor, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-03
- **Primary completion:** 2000-03
- **Final completion:** 2000-03
- **Target enrollment:** 428 (ACTUAL)
- **Last updated:** 2014-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00269867

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00269867, "Infliximab Plus Methotrexate for the Treatment of Rheumatoid Arthritis". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT00269867. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*